Fresh analysis suggests that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional lifestyle regimens.
Published data in a prominent health publication demonstrates that while obese people often shed substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these drugs need to be informed of the potential of quick rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain means a return to pre-treatment weight in about one and a half years.
Weighing Therapies
The analysis, which looked at 37 of trials involving over 9,000 of patients, compared the outcomes of the injectable medications with other pills.
The team emphasize that individuals who shed pounds through dieting typically see a slower weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Nutrition scientists suggest the mode of action of the drugs explains the accelerated regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 levels far above than normal might result in the system to produce less of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is uncontrolled, making binge eating a significant risk."
A Chronic Condition?
Health authorities suggest the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians say that, given the significant potential of relapse, the treatment is often long-term.
This perspective is supported by drug manufacturers, who state that the results "emphasize the persistent nature of obesity," similar to managing conditions like high blood pressure.
User Experiences
Individuals who have come off the jabs explain a sudden resurgence of appetite.
"It felt as if something flipping and you're instantly starving," said one woman.
The struggle is worsened if patients have not adopted lasting lifestyle or habit changes during therapy.
Widespread Adoption
Survey data show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and lasting health benefits hinges on ongoing behavioural changes.
